The protective properties of DPP-4 inhibitors in relation to oxidative and inflammatory parameters in MetS could be of significance for patients with T2DM, in particular in relation to vascular and adipose tissue dysfunction. Here, DPP4 is linked to type 2 diabetes mellitus.